<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1464">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432805</url>
  </required_header>
  <id_info>
    <org_study_id>2020-30</org_study_id>
    <secondary_id>2020-A01303-36</secondary_id>
    <nct_id>NCT04432805</nct_id>
  </id_info>
  <brief_title>Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19</brief_title>
  <acronym>LUSCOVIDPREG</acronym>
  <official_title>Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cohort prospective study.

      Objectives :

      Primary objective:

      To describe the lung ultrasound lesions in pregnant women in case of suspected or confirmed
      COVID-19

      Secondary objectives:

        -  To compare the lung ultrasound lesions with chest Computed Tomography -scanner (CT-Scan)
           lesions

        -  To evaluate the performances of the lung ultrasound to diagnose COVID-19 in pregnant
           women

        -  To evaluate predictive value of different lung ultrasound lesions for intensive care
           unit admission of pregnant women with suspected or confirmed COVID-19

        -  To describe the pregnancy issues of the study population

      Course of the study:

        -  Inclusion of pregnant suspected of having COVID-19 and cared following the service
           protocol

        -  Performing of lung ultrasound at bedside in labor ward or in COVID unit

      Primary outcome:

      Lung ultrasound lesions (and corresponding score) at the moment of the initial management of
      pregnant women suspected or confirmed with COVID-19 (having a nasopharyngeal Reverse
      Transcription Polymerase Chain Reaction (RT-PCR) SARS-CoV-2 and a chest CT-scan)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the lesions</measure>
    <time_frame>4 months</time_frame>
    <description>Description of the lesions in each of the 6 pulmonary quadrants on the right and left. Establishment of the ultrasound score corresponding to the sum of the scores attributed to each type of lesion in each quadrant (0: normal, 1: spaced comet tails, 2: curtain comet tails, 3: consolidation).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pregnant Women Suspected of COVID-19</condition>
  <arm_group>
    <arm_group_label>Pregnant women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant women suspected of COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Performing of lung ultrasound</intervention_name>
    <description>Performing of lung ultrasound at bedside in labor ward or in COVID unit</description>
    <arm_group_label>Pregnant women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years

          -  Gestational age greater than or equal to 22 weeks of gestation

          -  Pregnant women suspected of COVID-19 :

          -  already having a nasopharyngeal RT-PCR for the SARS-CoV-2

          -  AND having a chest CT-scan or waiting for this exam

          -  Women giving a writing consent to participate

        Exclusion Criteria:

          -  Women giving an opposition to participate

          -  Women not enough fluent in French to benefit from clear and intelligible information
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier ARNAUD, Director</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie BLANC, PH</last_name>
    <phone>491964672</phone>
    <phone_ext>+33</phone_ext>
    <email>julie.blanc@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie BLANC, PH</last_name>
      <phone>491964672</phone>
      <phone_ext>+33</phone_ext>
      <email>julie.blanc@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Julie BLANC, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

